Sep 26, 2024 / 10:00AM GMT
Andrew Newland - Angle PLC - Chief Executive, Executive Director
Good morning, everybody, and welcome to ANGLE's interim presentation for 2024. Welcome to the analysts in Berenberg's offices here in London and a very warm welcome to all our investors and shareholders who are on the webcast.
This is an important presentation. I'm intending to highlight some excellent progress in our pharma services business, which regrettably, however, has been weighed down by some challenging market conditions in our product sales business. And I'm going to explain the company's proactive response and the reason for our confidence in the new strategy, which is prioritizing large pharma investment in our large pharma strategy. As usual, I'll present the main part of the presentation, and then we'll move to questions and answers from the analysts, where I'll be joined by Ian Griffiths, our Finance Director.
So what exactly is our large pharma strategy? So last year, we decided to focus on our pharma services business on large pharma companies. And that was because we saw that some of the biopharma
Half Year 2024 Angle PLC Earnings Call Transcript
2 days ago
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers